Wellington Management Group LLP Makes New Investment in Compass Therapeutics, Inc. $CMPX

Wellington Management Group LLP purchased a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 222,505 shares of the company's stock, valued at approximately $423,000. Wellington Management Group LLP owned approximately 0.16% of Compass Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of CMPX. MPM Bioimpact LLC raised its position in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the period. Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics during the 4th quarter worth about $11,293,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after buying an additional 545,767 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Compass Therapeutics in the first quarter worth about $579,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded up $0.07 during trading hours on Friday, hitting $3.44. The company had a trading volume of 388,871 shares, compared to its average volume of 1,395,353. Compass Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $4.08. The firm has a market capitalization of $475.68 million, a P/E ratio of -7.64 and a beta of 1.50. The firm's fifty day moving average is $3.01 and its 200-day moving average is $2.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CMPX shares. Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a research report on Tuesday, July 1st. D. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim increased their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. According to MarketBeat.com, Compass Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $12.89.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.